CureVac Welcomes Myriam Mendila as New Chief Development Officer
- Dr. Mendila joins CureVac as Chief Development Officer with more than 20 years of global industry experience
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that Myriam Mendila has taken up her role as CureVac’s Chief Development Officer, as previously announced.